Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET
CRANFORD, N.J., May 29, 2024
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the
"Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company
dedicated to the development and commercialization of
first-in-class critical care products, today announced that it will
host an investor call on Monday, June 3,
2024 at 8:30 am ET to discuss
the topline results of its Phase 3 Trial of Mino-Lok antibiotic
lock solution.
Citius Chairman and CEO, Leonard
Mazur, will be joined by members of the management team to
discuss the results of the Phase 3 Trial and the clinical need for
Mino-Lok in patients with catheter-related bloodstream infections.
A question and answer period will follow management's
discussion.
Conference Call Details:
Date:
|
Monday, June 3,
2024
|
Time:
|
8:30 a.m. Eastern
Time
1-866-777-2509 (U.S. toll free)
|
Dial In:
|
1-412-317-5413
(international)
|
Webcast:
|
Register for the
webcast here. A replay will be available on the Citius website
(www.citiuspharma.com) for 90 days following the event.
|
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to
the development and commercialization of first-in-class critical
care products. The Company's diversified pipeline includes two
late-stage product candidates: Mino-Lok® and LYMPHIR™.
In May 2024, Citius announced
positive topline results of Mino-Lok, its antibiotic lock solution
to salvage catheters in patients with bloodstream infections. The
Biologics License Application for LYMPHIR, a novel IL-2R
immunotherapy for an initial indication in cutaneous T-cell
lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target
action date. Citius previously announced plans to form Citius
Oncology, a standalone publicly traded company with LYMPHIR as its
primary asset. LYMPHIR received orphan drug designation by the FDA
for the treatment of CTCL and PTCL. In addition, Citius completed
enrollment in its Phase 2b trial of
CITI-002 (Halo-Lido), a topical formulation for the relief of
hemorrhoids. For more information, please visit
www.citiuspharma.com.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-host-investor-call-to-discuss-topline-results-of-phase-3-trial-of-mino-lok-antibiotic-lock-solution-302157598.html
SOURCE Citius Pharmaceuticals, Inc.